

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

03 December 2020 (03.12.2020)



WIPO | PCT



(10) International Publication Number

WO 2020/242984 A1

(51) International Patent Classification:

C07K 14/315 (2006.01) C12N 7/00 (2006.01)

A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2020/034328

(22) International Filing Date:

22 May 2020 (22.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/852,791 24 May 2019 (24.05.2019) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **SABIN, Leah**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KYRATSOUS, Christos**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MOLLER-TANK, Sven**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **WU, Rita**; FisherBroyles, LLP, 945 East Paces Ferry Road, Suite 2000, Atlanta, Georgia 30326 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MODIFIED VIRAL PARTICLES AND USES THEREOF

(57) Abstract: Provided herein are compositions and methods for adapting adeno-associated virus (AAV) particles comprising capsids of non-primate animal AAV, remote AAV, or a combination thereof. AAV adapted accordingly may be a viable gene therapy platform for the treatment of a patient in need thereof, and may be particularly useful in patients excluded from current treatment modalities involving current therapeutic AAV particles due to their high titer of antibodies against the current therapeutic AAV particles.



WO 2020/242984 A1